Company · Healthcare
Tokyo
Every investor coverage indicates participated in a round Terumo Corporation raised.
Companies Terumo Corporation acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Wataru Ninokura | Director of Essential Medical Products | Uniseed, Brandon Capital |
Stories naming Terumo Corporation. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Uniseed-backed Australian medtech Q-Sera's blood-clotting tube technology has debuted in Japan via Terumo's VenoJect II launch; the post also credits MRCF and UniQuest Extension Fund as backers.
Q-Sera's rapid-clotting blood tube technology has gone to market in Japan via Terumo's VenoJect II launch; the Melbourne startup's backers include MRCF, Uniseed and the UniQuest Extension Fund.
Index of the venture firm's portfolio updates: financing rounds for AdvanCell and ENA Respiratory, grant awards via incubator programs, two closes of Fund Six, board hires, and Myricx Bio's completed sale to Novartis.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Uniseed·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Cut Through Venture·SmartCompany·AFR Technology·Startup Daily·Startup Daily·SmartCompany·Startup Daily·Startup Daily·Startup Daily·@AuManufacturing·finance.yahoo.com·enarespiratory.com·Mirage News·Forbes Australia·advancell.com.au·Forbes Australia·datapile.co·Dealroom·Forbes Australia·datapile.co·Biotech Dispatch·fundedstartupsdaily.com·fundedstartupsdaily.com·Forbes Australia